Adage Capital Partners
ZNTL icon

Adage Capital Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Adage Capital Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-301,667
Closed -$6.05M – 938
2023
Q3 		$6.05M Sell
301,667
-253,333
-46% -$6.43M 0.01% 644
2023
Q2 		$15.7M Buy
+555,000
New +$13.3M 0.03% 471

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners's ZNTL Position: Q4 2023 in Review

Adage Capital Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 301,667 shares — an estimated $6.05M sold.

Adage Capital Partners first reported a position in ZNTL in Q2 2023 and held it in 2 quarters. The position peaked at $15.7M in Q2 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • Adage Capital Partners reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Adage Capital Partners sold 301,667 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $6.05M.
  • Adage Capital Partners first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Adage Capital Partners's Zentalis Pharmaceuticals position peaked at $15.7M in Q2 2023.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Adage Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.